Cargando…
Transcription factors and potential therapeutic targets for pulmonary hypertension
Pulmonary hypertension (PH) is a refractory and fatal disease characterized by excessive pulmonary arterial cell remodeling. Uncontrolled proliferation and hypertrophy of pulmonary arterial smooth muscle cells (PASMCs), dysfunction of pulmonary arterial endothelial cells (PAECs), and abnormal periva...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064017/ https://www.ncbi.nlm.nih.gov/pubmed/37009479 http://dx.doi.org/10.3389/fcell.2023.1132060 |
_version_ | 1785017819928199168 |
---|---|
author | Yang, Liu Wan, Naifu Gong, Fanpeng Wang, Xianfeng Feng, Lei Liu, Guizhu |
author_facet | Yang, Liu Wan, Naifu Gong, Fanpeng Wang, Xianfeng Feng, Lei Liu, Guizhu |
author_sort | Yang, Liu |
collection | PubMed |
description | Pulmonary hypertension (PH) is a refractory and fatal disease characterized by excessive pulmonary arterial cell remodeling. Uncontrolled proliferation and hypertrophy of pulmonary arterial smooth muscle cells (PASMCs), dysfunction of pulmonary arterial endothelial cells (PAECs), and abnormal perivascular infiltration of immune cells result in pulmonary arterial remodeling, followed by increased pulmonary vascular resistance and pulmonary pressure. Although various drugs targeting nitric oxide, endothelin-1 and prostacyclin pathways have been used in clinical settings, the mortality of pulmonary hypertension remains high. Multiple molecular abnormalities have been implicated in pulmonary hypertension, changes in numerous transcription factors have been identified as key regulators in pulmonary hypertension, and a role for pulmonary vascular remodeling has been highlighted. This review consolidates evidence linking transcription factors and their molecular mechanisms, from pulmonary vascular intima PAECs, vascular media PASMCs, and pulmonary arterial adventitia fibroblasts to pulmonary inflammatory cells. These findings will improve the understanding of particularly interactions between transcription factor-mediated cellular signaling pathways and identify novel therapies for pulmonary hypertension. |
format | Online Article Text |
id | pubmed-10064017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100640172023-04-01 Transcription factors and potential therapeutic targets for pulmonary hypertension Yang, Liu Wan, Naifu Gong, Fanpeng Wang, Xianfeng Feng, Lei Liu, Guizhu Front Cell Dev Biol Cell and Developmental Biology Pulmonary hypertension (PH) is a refractory and fatal disease characterized by excessive pulmonary arterial cell remodeling. Uncontrolled proliferation and hypertrophy of pulmonary arterial smooth muscle cells (PASMCs), dysfunction of pulmonary arterial endothelial cells (PAECs), and abnormal perivascular infiltration of immune cells result in pulmonary arterial remodeling, followed by increased pulmonary vascular resistance and pulmonary pressure. Although various drugs targeting nitric oxide, endothelin-1 and prostacyclin pathways have been used in clinical settings, the mortality of pulmonary hypertension remains high. Multiple molecular abnormalities have been implicated in pulmonary hypertension, changes in numerous transcription factors have been identified as key regulators in pulmonary hypertension, and a role for pulmonary vascular remodeling has been highlighted. This review consolidates evidence linking transcription factors and their molecular mechanisms, from pulmonary vascular intima PAECs, vascular media PASMCs, and pulmonary arterial adventitia fibroblasts to pulmonary inflammatory cells. These findings will improve the understanding of particularly interactions between transcription factor-mediated cellular signaling pathways and identify novel therapies for pulmonary hypertension. Frontiers Media S.A. 2023-03-17 /pmc/articles/PMC10064017/ /pubmed/37009479 http://dx.doi.org/10.3389/fcell.2023.1132060 Text en Copyright © 2023 Yang, Wan, Gong, Wang, Feng and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Yang, Liu Wan, Naifu Gong, Fanpeng Wang, Xianfeng Feng, Lei Liu, Guizhu Transcription factors and potential therapeutic targets for pulmonary hypertension |
title | Transcription factors and potential therapeutic targets for pulmonary hypertension |
title_full | Transcription factors and potential therapeutic targets for pulmonary hypertension |
title_fullStr | Transcription factors and potential therapeutic targets for pulmonary hypertension |
title_full_unstemmed | Transcription factors and potential therapeutic targets for pulmonary hypertension |
title_short | Transcription factors and potential therapeutic targets for pulmonary hypertension |
title_sort | transcription factors and potential therapeutic targets for pulmonary hypertension |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064017/ https://www.ncbi.nlm.nih.gov/pubmed/37009479 http://dx.doi.org/10.3389/fcell.2023.1132060 |
work_keys_str_mv | AT yangliu transcriptionfactorsandpotentialtherapeutictargetsforpulmonaryhypertension AT wannaifu transcriptionfactorsandpotentialtherapeutictargetsforpulmonaryhypertension AT gongfanpeng transcriptionfactorsandpotentialtherapeutictargetsforpulmonaryhypertension AT wangxianfeng transcriptionfactorsandpotentialtherapeutictargetsforpulmonaryhypertension AT fenglei transcriptionfactorsandpotentialtherapeutictargetsforpulmonaryhypertension AT liuguizhu transcriptionfactorsandpotentialtherapeutictargetsforpulmonaryhypertension |